Living related donor kidney transplantation in patients with a positive flow cytometry crossmatch.
Hong
J H
JH
Department of Surgery, State University of New York, Health Science Center at Brooklyn 11203, USA.
Sadeghian
M
M
Sumrani
N
N
Distant
D A
DA
Sommer
B G
BG
Norin
A J
AJ
D000206:Actuarial Analysis; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005006:Ethnicity; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology; D006085:Graft Survival; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011237:Predictive Value of Tests; D044469:Racial Groups; D015996:Survival Rate
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine